Akkermansia Muciniphilia and Metabolic Side Effects of ADT
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The overriding objectives of this study are:
1. Primary outcomes:
1. To confirm that administration of oral acetate increases the proportion of A.
muciniphilia in the stool samples of patients with metastatic, castration-sensitive
prostate cancer compared to placebo.
2. To confirm tolerability and assess for side effects of delayed oral acetate
supplementation.
2. Secondary outcomes:
1. To determine if increased counts of A. muciniphilia correlate with improved
metabolic parameters and improved bone health.